FDA approval of a dual hot flashes/osteoporosis indication for Pfizer Inc.’s Duavee (conjugated estrogens/bazedoxifene) gives the big pharma a novel combination pill that hits two needs for the same target population of postmenopausal women.
It also creates an opportunity for Pfizer to try to recapture the type of broad use once enjoyed by Wyeth’s Premarin/Prempro hormone replacement therapy franchise, sales of which fell dramatically in